4 Patients Randomized. $1,250 Per Randomized Patient.

Clinical research sites running multiple active protocols face a resource allocation problem that compounds over time. Coordinators are stretched across studies. Referral networks that served one indication may not serve the next.

When a Sanofi-sponsored Acne study required enrollment beyond what the site's organic pipeline could support, the site faced a decision common to high-performing sites that still miss timelines: where do the additional patients come from, and who bears the cost if they don't arrive. In-house digital outreach exceeded what the site team could manage alongside active study operations. External vendors presented the same fundamental risk: spend first, results uncertain.

Four additional randomized patients were needed. The protocol timeline was defined. The site required a commitment, not a projection.

The campaign delivered 4 randomized patients against a $5,000 investment, a cost per randomized patient of $1,250.

Per-patient site fees in Phase II-III studies typically range from $3,000 to $15,000 per randomized patient. At an estimated $3,000 to $15,000 per-patient site fee, 4 randomized patients represents a potential $12,000 to $60,000 in patient revenue against a $5,000 campaign investment.

The contractual randomization commitment meant the site team could plan around a defined outcome. Enrollment variance, one of the primary drivers of timeline slippage and sponsor friction, was transferred to Clinical Enroll before the campaign launched.